Advanced Search
WANG Ziyuan, TAO Hui, XIAO Yingxue, et al. Network pharmacology-based study of the mechanism of Ginkgo biloba extract (GBE) in the treatment of atherosclerosis by activating PPARγ[J]. J China Pharm Univ, 2025, 56(2): 225 − 235. DOI: 10.11665/j.issn.1000-5048.2024032301
Citation: WANG Ziyuan, TAO Hui, XIAO Yingxue, et al. Network pharmacology-based study of the mechanism of Ginkgo biloba extract (GBE) in the treatment of atherosclerosis by activating PPARγ[J]. J China Pharm Univ, 2025, 56(2): 225 − 235. DOI: 10.11665/j.issn.1000-5048.2024032301

Network pharmacology-based study of the mechanism of Ginkgo biloba extract (GBE) in the treatment of atherosclerosis by activating PPARγ

More Information
  • Received Date: March 22, 2024
  • To investigate the effect of Ginkgo biloba extract (GBE) on lipids accumulation and the progression of atherosclerosis(AS), ApoE-/- mice fed with HFD were injected i.g. with two different doses of GBE (GBE-L 50 mg/(kg·d) or GBE-H 150 mg/(kg·d)) for 9 weeks. The core targets and potential mechanisms of GBE therapy for AS were investigated using network pharmacological target prediction. Subsequently, oxidized low-density lipoprotein (ox-LDL)-induced THP-1 was used to investigate the effect of GBE on foam cell formation through oil red staining and Dil-oxLDL fluorescent staining. The mRNA alterations in cholesterol uptake and efflux receptors were detected by real-time quantitative PCR. Finally, the impact of GBE on the expression of PPARγ as the core target was assessed through Western blot and immunofluorescence. It was found that GBE improved serum lipid profile, reduced necrotic cores and lipid deposition in aortic root plaques, and decreased the level of inflammatory factors in serum of ApoE-/- mice. Moreover, GBE treatment reduced the level of intracellular lipid accumulation and inhibited cholesterol uptake and efflux to alleviate foam cell formation. GBE activated PPARγ to enhance ABCA1/ABCG1-induced cholesterol efflux in THP-1. These results suggest that GBE can suppress lipid accumulation and alleviate foam cell formation by activating PPARγ pathway.

  • [1]
    Libby P. The changing landscape of atherosclerosis[J]. Nature, 2021, 592(7855): 524-533. doi: 10.1038/s41586-021-03392-8
    [2]
    Libby P, Buring JE, Badimon L, et al. Atherosclerosis[J]. Nat Rev Dis Primers, 2019, 5(1): 56. doi: 10.1038/s41572-019-0106-z
    [3]
    Fan JL, Watanabe T. Atherosclerosis: known and unknown[J]. Pathol Int, 2022, 72(3): 151-160. doi: 10.1111/pin.13202
    [4]
    Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport[J]. Circ Res, 2019, 124(10): 1505-1518. doi: 10.1161/CIRCRESAHA.119.312617
    [5]
    Liu XF, Wu JS, Tian RM, et al. Targeting foam cell formation and macrophage polarization in atherosclerosis: the therapeutic potential of rhubarb[J]. Biomed Pharmacother, 2020, 129: 110433. doi: 10.1016/j.biopha.2020.110433
    [6]
    Wang DD, Yang Y, Lei YN, et al. Targeting foam cell formation in atherosclerosis: therapeutic potential of natural products[J]. Pharmacol Rev, 2019, 71(4): 596-670. doi: 10.1124/pr.118.017178
    [7]
    Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL[J]. Arterioscler Thromb Vasc Biol, 2007, 27(5): 1132-1138. doi: 10.1161/ATVBAHA.106.138347
    [8]
    Adorni MP, Zimetti F, Billheimer JT, et al. The roles of different pathways in the release of cholesterol from macrophages[J]. J Lipid Res, 2007, 48(11): 2453-2462. doi: 10.1194/jlr.M700274-JLR200
    [9]
    Chiu YL, Tsai WC, Wu CH, et al. Ginkgo biloba induces thrombomodulin expression and tissue-type plasminogen activator secretion via the activation of Krüppel-like factor 2 within endothelial cells[J]. Am J Chin Med, 2020, 48(2): 357-372.
    [10]
    Wang Y, Xu YY, Xu XW, et al. Ginkgo biloba extract ameliorates atherosclerosis via rebalancing gut flora and microbial metabolism[J]. Phytother Res, 2022, 36 (6): 2463-2480.
    [11]
    Liu HJ, Wang XL, Zhang L, et al. Inhibitions of vascular endothelial growth factor expression and foam cell formation by EGb 761, a special extract of Ginkgo biloba, in oxidatively modified low-density lipoprotein-induced human THP-1 monocytes cells[J]. Phytomedicine, 2009, 16(2/3): 138-145.
    [12]
    Li TH. Ginkgo biloba extract (EGb761) inhibiting smoothmuscle foam cell formation and the underlying mechanisms (银杏叶提取物EGb761抑制平滑肌细胞泡沫化的机制研究)[D]. Xi’an: Air Force Medical University, 2019.
    [13]
    Tall AR, Thomas DG, Gonzalez-Cabodevilla AG, et al. Addressing dyslipidemic risk beyond LDL-cholesterol[J]. J Clin Invest, 2022, 132(1): e148559. doi: 10.1172/JCI148559
    [14]
    Bäck M, Yurdagul A Jr, Tabas I, et al. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities[J]. Nat Rev Cardiol, 2019, 16(7): 389-406.
    [15]
    Miao M, Wang X, Liu T, et al. Targeting PPARs for therapy of atherosclerosis: a review[J]. Int J Biol Macromol, 2023, 242 (Pt 2): 125008.
    [16]
    Singh S, Changkija S, Mudgal R, et al. Bioactive components to inhibit foam cell formation in atherosclerosis[J]. Mol Biol Rep, 2022, 49(3): 2487-2501. doi: 10.1007/s11033-021-07039-9
    [17]
    Ference BA, Graham I, Tokgozoglu L, et al. Impact of lipids on cardiovascular health: JACC health promotion series[J]. J Am Coll Cardiol, 2018, 72(10): 1141-1156. doi: 10.1016/j.jacc.2018.06.046
    [18]
    Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J, 2017, 38(32): 2459-2472. doi: 10.1093/eurheartj/ehx144
    [19]
    Raja V, Aguiar C, Alsayed N, et al. Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook[J]. Atherosclerosis, 2023, 383: 117312. doi: 10.1016/j.atherosclerosis.2023.117312
    [20]
    Tang HY, Xing CH, Zhang MM. Research progress on role of ABCA1 in regulation of cell death in atherosclerosis[J]. Lab Med Clin (检验医学与临床), 2023, 20(13): 1945-1949.
    [21]
    Westerterp M, Bochem AE, Yvan-Charvet L, et al. ATP-binding cassette transporters, atherosclerosis, and inflammation[J]. Circ Res, 2014, 114(1): 157-170. doi: 10.1161/CIRCRESAHA.114.300738
    [22]
    Xu PF, Zhai YG, Wang J. The role of PPAR and its cross-talk with CAR and LXR in obesity and atherosclerosis[J]. Int J Mol Sci, 2018, 19(4): 1260. doi: 10.3390/ijms19041260
    [23]
    Doran AC. Inflammation resolution: implications for atherosclerosis[J]. Circ Res, 2022, 130(1): 130-148. doi: 10.1161/CIRCRESAHA.121.319822
    [24]
    Pradhan AD, Aday AW, Rose LM, et al. Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy[J]. Circulation, 2018, 138(2): 141-149. doi: 10.1161/CIRCULATIONAHA.118.034645
    [25]
    Everett BM, MacFadyen JG, Thuren T, et al. Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS trial[J]. J Am Coll Cardiol, 2020, 76(14): 1660-1670. doi: 10.1016/j.jacc.2020.08.011
    [26]
    Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med, 2019, 381(26): 2497-2505. doi: 10.1056/NEJMoa1912388
    [27]
    Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease[J]. N Engl J Med, 2020, 383(19): 1838-1847. doi: 10.1056/NEJMoa2021372
    [28]
    Ibañez B, Fuster V. CANTOS: a gigantic proof-of-concept trial[J]. Circ Res, 2017, 121(12): 1320-1322. doi: 10.1161/CIRCRESAHA.117.312200
    [29]
    Schenone AL, Menon V. Colchicine in pericardial disease: from the underlying biology and clinical benefits to the drug-drug interactions in cardiovascular medicine[J]. Curr Cardiol Rep, 2018, 20(8): 62. doi: 10.1007/s11886-018-1008-5
    [30]
    Singh SK, Srivastav S, Castellani RJ, et al. Neuroprotective and antioxidant effect of Ginkgo biloba extract against AD and other neurological disorders[J]. Neurotherapeutics, 2019, 16(3): 666-674. doi: 10.1007/s13311-019-00767-8
    [31]
    Sun J. A comprehensive study on the effects of Ginkgo biloba extract on the mechanism of atherosclerosis(银杏叶提取物对动脉粥样硬化相关机制影响的综合研究)[D]. Dalian: Dalian Medical University, 2015.
    [32]
    Ou HC, Hsieh YL, Yang NC, et al. Ginkgo biloba extract attenuates oxLDL-induced endothelial dysfunction via an AMPK-dependent mechanism[J]. J Appl Physiol (1985), 2013, 114 (2): 274-285.
    [33]
    Jiao YB, Rui YC, Li TJ, et al. Expression of pro-inflammatory and anti-inflammatory cytokines in brain of atherosclerotic rats and effects of Ginkgo biloba extract[J]. Acta Pharmacol Sin, 2005, 26(7): 835-839. doi: 10.1111/j.1745-7254.2005.00106.x
  • Related Articles

    [1]LIU Yuhong, ZHANG Fangfang, LIU Jianxing, LIU Yue, YANG Yue, JIN Liang. Interplay between non-coding RNA and insulin signaling pathway and its clinical application[J]. Journal of China Pharmaceutical University, 2021, 52(3): 279-286. DOI: 10.11665/j.issn.1000-5048.20210303
    [2]MEI Jiahao, HONG Ze, WANG Chen. Advances of drugs in targeting cGAS-STING signaling pathway[J]. Journal of China Pharmaceutical University, 2020, 51(3): 249-259. DOI: 10.11665/j.issn.1000-5048.20200301
    [3]TAN Chengning, HUANG Jinghan, LI Chunhong, XIA Zhining, YANG Fengqing. Applications of proteomics in the study of cell signal pathways[J]. Journal of China Pharmaceutical University, 2017, 48(4): 384-395. DOI: 10.11665/j.issn.1000-5048.20170402
    [4]WANG Xue, ZHANG Pinghu. Advances in research on the modulation of autophagy by Ras/Raf/MEK/ERK signaling pathway[J]. Journal of China Pharmaceutical University, 2017, 48(1): 110-116. DOI: 10.11665/j.issn.1000-5048.20170117
    [5]HUANG Shaoliang, ZHAO Li, GUO Qinglong, WU Yulin. Advances of Hedgehog pathway in tumor resistance[J]. Journal of China Pharmaceutical University, 2016, 47(3): 259-266. DOI: 10.11665/j.issn.1000-5048.20160302
    [6]XIANG Min, ZHANG Yaqin, WU Pingping, GAO Zhenyu. Effect of block of AGEs-RAGE pathway on the migration of VSMCs[J]. Journal of China Pharmaceutical University, 2016, 47(2): 199-203. DOI: 10.11665/j.issn.1000-5048.20160212
    [7]LIU Li-na, SUN Zhi-guang, CAI Xue-ting, CAO Peng, LU Yin, SHAO Ming, CHEN Guang-mei, SHI Hui-lian. Quercetin improves TNF-α induced intestinal barrier dysfunction in Caco-2 cells[J]. Journal of China Pharmaceutical University, 2012, 43(6): 541-545.
    [8]XU Ling-jie, LI Cong, ZHANG Mian, DAI Yue, HUANG Fang. Effect of the ethyl acetate extract of Farfarae Flos on inflammatory factors[J]. Journal of China Pharmaceutical University, 2011, 42(1): 64-67.
    [10]Study on the Relationship of Dexamethasone-induced Mouse Thymocytes Apoptosis Process with ERK1/2 MAPK Pathway and Calcium Ion Concentration[J]. Journal of China Pharmaceutical University, 2004, (1): 79-83.

Catalog

    Article views (196) PDF downloads (31) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return